Previously, we performed a genome-wide RNAi screen for tyrosine kinase genes whose function is critical for breast cancer cell survival. Bruton's Tyrosine kinase (BTK) was among those genes whose knockdown causes the most significant reduction in survival. BTK is a critical regulator of B cell receptor (BCR) signaling. Mutations in the btk gene lead to B cell deficiency manifested as X-linked agammaglobulinemia in humans and the related but less severe X-linked immunodeficiency (xid) in mice. The role of BTK in B-cell development and B-cell malignancies has been extensively studied. In haematopoietic cells, BTK is involved in multiple signal-transduction pathways regulating survival, activation, proliferation, and differentiation of B-lymphocytes.
Drug targets for cancer: BTK research reagents
Other vital drug targets for cancer likeBTK:
Kokabee L, Wang X, Sevinsky CJ, et al. Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biology & Therapy. 2015;16(11):1604-1615.